This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
united states | 3901 |
public health | 1383 |
health care | 920 |
infectious diseases | 709 |
united kingdom | 526 |
cystic fibrosis | 473 |
infectious disease | 369 |
clinical signs | 369 |
lyme disease | 360 |
respiratory syndrome | 344 |
design method | 318 |
acute respiratory | 312 |
infection control | 304 |
disease control | 299 |
new york | 289 |
risk factors | 282 |
developing countries | 278 |
climate change | 264 |
severe acute | 257 |
hiv aids | 253 |
may also | 245 |
world health | 235 |
mental health | 225 |
epithelial cells | 212 |
avian influenza | 211 |
health organization | 210 |
united nations | 208 |
west nile | 202 |
respiratory tract | 199 |
cord uid | 191 |
doc id | 191 |
per year | 186 |
early warning | 186 |
bone marrow | 185 |
nile virus | 185 |
pediatric patients | 182 |
lung function | 180 |
may occur | 178 |
staphylococcus aureus | 175 |
incubation period | 172 |
north america | 172 |
escherichia coli | 171 |
increased risk | 162 |
emerging infectious | 161 |
intensive care | 157 |
human rights | 157 |
hand hygiene | 153 |
mg kg | 153 |
lung disease | 149 |
states background | 148 |
disaster risk | 146 |
high risk | 143 |
biological weapons | 142 |
infectious agents | 142 |
virus infection | 141 |
young children | 135 |
human health | 134 |
million people | 134 |
animal health | 134 |
nervous system | 133 |
pseudomonas aeruginosa | 133 |
confirmed cases | 131 |
clinical trials | 130 |
years old | 128 |
health insurance | 127 |
medical care | 124 |
cell lines | 124 |
world war | 124 |
developed countries | 123 |
influenza virus | 122 |
risk reduction | 121 |
pregnant women | 121 |
advisory committee | 120 |
mean age | 119 |
national health | 118 |
antimicrobial resistance | 118 |
critical care | 116 |
th century | 115 |
adverse events | 115 |
antibiotic therapy | 114 |
differential diagnosis | 109 |
influenza pandemic | 108 |
sickle cell | 107 |
central nervous | 107 |
feral cats | 106 |
care unit | 106 |
control measures | 105 |
care settings | 105 |
canine distemper | 104 |
natural disasters | 103 |
may lead | 102 |
middle east | 101 |
hong kong | 101 |
risk factor | 101 |
social distancing | 100 |
systematic review | 99 |
gastrointestinal tract | 98 |
yellow fever | 98 |
antibiotic resistance | 98 |
coronavirus disease | 98 |
risk assessment | 97 |
hiv infection | 97 |
lymph nodes | 97 |
median age | 97 |
weight loss | 97 |
member states | 96 |
older adults | 95 |
statistically significant | 95 |
may result | 95 |
health systems | 95 |
per cent | 95 |
health services | 94 |
infl uenza | 94 |
least one | 94 |
ebola virus | 94 |
upper respiratory | 93 |
vaccine safety | 93 |
recent years | 93 |
antibiotic use | 93 |
hemorrhagic fever | 92 |
among children | 91 |
immune response | 91 |
resistant staphylococcus | 90 |
age years | 90 |
world bank | 90 |
side effects | 89 |
airway epithelial | 89 |
may cause | 88 |
many countries | 88 |
young adults | 88 |
liver oil | 88 |
stem cell | 88 |
influenza viruses | 87 |
european union | 87 |
may include | 87 |
homeland security | 86 |
south america | 86 |
disaster management | 86 |
care workers | 86 |
respiratory infections | 85 |
healthcare workers | 85 |
infected animals | 85 |
respiratory syncytial | 84 |
cod liver | 84 |
saharan africa | 83 |
york city | 83 |
respiratory disease | 83 |
chemical weapons | 83 |
online labour | 82 |
human services | 82 |
blood cell | 82 |
primary care | 81 |
determine whether | 81 |
pulmonary function | 81 |
mortality rates | 81 |
cell disease | 81 |
zoonotic diseases | 81 |
endemic areas | 81 |
patient care | 81 |
red blood | 80 |
direct contact | 80 |
herd immunity | 80 |
immunodeficiency virus | 79 |
chart review | 79 |
syncytial virus | 79 |
clinical trial | 79 |
new zealand | 79 |
domestic animals | 79 |
care facilities | 78 |
international order | 78 |
past years | 78 |
clinical disease | 78 |
west africa | 78 |
less likely | 78 |
even though | 78 |
disease outbreaks | 78 |
affected animals | 77 |
novel coronavirus | 77 |
affective polarization | 77 |
will continue | 77 |
large numbers | 76 |
decision making | 76 |
inhalational anthrax | 76 |
health service | 75 |
high levels | 75 |
animal diseases | 75 |
mouth disease | 75 |
pandemic influenza | 75 |
antibiotic treatment | 75 |
fatality rate | 74 |
highly pathogenic | 74 |
warning systems | 74 |
data suggest | 74 |
antimicrobial therapy | 74 |
immune system | 74 |
risk management | 73 |
within hours | 73 |
abdominal pain | 73 |
porcine reproductive | 73 |
body fluids | 73 |
disease surveillance | 73 |
medical center | 73 |
human immunodeficiency | 73 |
prospective study | 72 |
immunization practices | 72 |
chain reaction | 72 |
surveillance system | 72 |
biological agents | 72 |
significant difference | 72 |
income countries | 72 |
one patient | 71 |
health outcomes | 71 |
new cases | 71 |
health system | 71 |
soviet union | 71 |
war ii | 71 |
commonly used | 70 |
mortality rate | 70 |
backyard poultry | 70 |
age groups | 70 |
important role | 70 |
case fatality | 70 |
care system | 69 |
see chapter | 69 |
task force | 69 |
blood cultures | 69 |
borne diseases | 69 |
significant differences | 69 |
zoonotic disease | 69 |
polymerase chain | 69 |
cohort study | 68 |
see table | 68 |
st century | 68 |
global health | 68 |
family members | 68 |
large number | 68 |
leading cause | 68 |
latin america | 68 |
respiratory distress | 67 |
age group | 67 |
lower respiratory | 67 |
otitis media | 67 |
significantly higher | 66 |
will likely | 66 |
necropsy findings | 66 |
nutritional status | 66 |
care providers | 66 |
general population | 66 |
states department | 66 |
south africa | 65 |
reported cases | 65 |
heart disease | 65 |
disease may | 65 |
will require | 65 |
world trade | 65 |
adverse effects | 65 |
liver disease | 65 |
federal government | 65 |
vaccine development | 65 |
emerging infections | 64 |
communicable diseases | 64 |
cell surface | 64 |
backyard flocks | 64 |
developing world | 64 |
plasma membrane | 64 |
one study | 64 |
within days | 63 |
will need | 63 |
cell line | 63 |
blood transfusion | 62 |
asian americans | 62 |
food security | 62 |
syndrome virus | 62 |
protective equipment | 62 |
retrospective chart | 62 |
working group | 62 |
pediatric oncology | 62 |
data collection | 61 |
clostridium difficile | 61 |
equine encephalitis | 61 |
adult patients | 61 |
clinical presentation | 61 |
mucous membranes | 61 |
american dream | 61 |
air pollution | 61 |
factors associated | 61 |
contaminated food | 61 |
total number | 61 |
will also | 61 |
care facility | 61 |
widely used | 61 |
attenuated live | 60 |
infection may | 60 |
disease caused | 60 |
viral infections | 60 |
animals may | 60 |
population density | 59 |
veterinary medicine | 59 |
per day | 59 |
personal protective | 59 |
higher risk | 59 |
money laundering | 59 |
gene expression | 59 |
person transmission | 59 |
north american | 59 |
human disease | 59 |
first year | 58 |
economic impact | 58 |
standard precautions | 58 |
traumatic stress | 58 |
wide range | 58 |
health authorities | 58 |
immune responses | 58 |
fatty acids | 58 |
virus vaccine | 57 |
drinking water | 57 |
pulmonary disease | 57 |
supportive care | 57 |
phase iii | 57 |
two years | 57 |
infectious agent | 57 |
campylobacter jejuni | 57 |
influenza vaccine | 57 |
blood cells | 57 |
rural areas | 57 |
drug administration | 57 |
biological weapon | 56 |
control practices | 56 |
emergency response | 56 |
encephalitis virus | 56 |
common cause | 56 |
cases per | 56 |
life cycle | 56 |
study period | 56 |
chronic diseases | 55 |
health professionals | 55 |
closely related | 55 |
disease prevention | 55 |
fresh produce | 55 |
clinical practice | 55 |
life expectancy | 55 |
los angeles | 55 |
european countries | 55 |
term care | 55 |
critically ill | 55 |
respiratory failure | 54 |
may develop | 54 |
natural hazards | 54 |
blood donors | 54 |
private sector | 54 |
respiratory symptoms | 53 |
lymphoblastic leukemia | 53 |
growth rate | 53 |
patients received | 53 |
vaccination program | 53 |
new vaccines | 53 |
distemper virus | 53 |
per capita | 53 |
inflammatory response | 53 |
biological warfare | 53 |
gene therapy | 53 |
clinical manifestations | 53 |
mycobacterium tuberculosis | 53 |
health status | 52 |
social media | 52 |
surveillance systems | 52 |
become infected | 52 |
emergency department | 52 |
test results | 52 |
significantly lower | 52 |
south korea | 52 |
acute lymphoblastic | 52 |
naturally occurring | 52 |
causative agent | 51 |
clinical features | 51 |
also known | 51 |
borrelia burgdorferi | 51 |
pulmonary exacerbation | 51 |
emerging diseases | 51 |
control group | 51 |
also may | 51 |
renal failure | 51 |
law enforcement | 51 |
rotavirus infection | 51 |
salmonella dublin | 51 |
emerging pathogens | 51 |
may provide | 50 |
clinical course | 50 |
less common | 50 |
severe cases | 50 |
controlled trial | 50 |
preventable diseases | 50 |
results suggest | 50 |
spotted fever | 50 |
ng ml | 50 |
lessons learned | 50 |
significant increase | 50 |
nipah virus | 50 |
amino acid | 50 |
physical examination | 50 |
cause disease | 50 |
antimicrobial agents | 50 |
health officials | 50 |
severe disease | 50 |
years ago | 50 |
home care | 50 |
many years | 50 |
acquired pneumonia | 50 |
may help | 50 |
allergic rhinitis | 50 |
member countries | 49 |
diarrheal disease | 49 |
natural history | 49 |
spinal cord | 49 |
also used | 49 |
southeast asia | 49 |
low levels | 49 |
emergency management | 49 |
epidemiologic studies | 49 |
airway epithelia | 49 |
vaccination coverage | 49 |
childhood asthma | 48 |
warning system | 48 |
patients receiving | 48 |
industrialized countries | 48 |
first time | 48 |
bovine tuberculosis | 48 |
commercially available | 48 |
bacterial infections | 48 |
national institutes | 48 |
tailed deer | 48 |
disease transmission | 48 |
us department | 48 |
professional development | 48 |
food safety | 48 |
bronchial epithelial | 48 |
bacterial infection | 47 |
high mortality | 47 |
may become | 47 |
peripheral blood | 47 |
drug users | 47 |
close contact | 47 |
animal disease | 47 |
disease outbreak | 47 |
wild animals | 47 |
cell culture | 47 |
adopted children | 47 |
tract infections | 47 |
two patients | 47 |
cases reported | 47 |
per week | 47 |
water supplies | 46 |
disease severity | 46 |
high prevalence | 46 |
additional file | 46 |
childhood cancer | 46 |
may require | 46 |
rabies virus | 46 |
dog food | 46 |
streptococcus pneumoniae | 46 |
airborne transmission | 46 |
pulmonary exacerbations | 46 |
sierra leone | 45 |
animals will | 45 |
red cross | 45 |
soft tissue | 45 |
twice daily | 45 |
viral hemorrhagic | 45 |
th percentile | 45 |
years later | 45 |
health policy | 45 |
white blood | 45 |
health departments | 45 |
medical supplies | 45 |
american academy | 45 |
patients may | 45 |
typhoid fever | 45 |
conjugate vaccine | 45 |
laboratory workers | 45 |
wide variety | 44 |
national surveillance | 44 |
major cause | 44 |
long term | 44 |
liberal international | 44 |
human cases | 44 |
health problems | 44 |
health promotion | 44 |
rocky mountain | 44 |
nosocomial infections | 44 |
human population | 44 |
jakob disease | 44 |
fev predicted | 44 |
newly diagnosed | 44 |
kg day | 44 |
forced migration | 43 |
hematopoietic stem | 43 |
sustainable development | 43 |
haemophilus influenzae | 43 |
communicable disease | 43 |
risks associated | 43 |
infected persons | 43 |
first case | 43 |
respiratory illness | 43 |
old male | 43 |
international travel | 43 |
case report | 43 |
microbiology laboratory | 43 |
platelet count | 43 |
different countries | 43 |
animal models | 43 |
airway surface | 43 |
oncology patients | 43 |
atopic dermatitis | 43 |
log reduction | 43 |
trade center | 43 |
diarrhea virus | 42 |
immunocompromised patients | 42 |
bacillus anthracis | 42 |
universal health | 42 |
greater risk | 42 |
national institute | 42 |
mass destruction | 42 |
perfringens type | 42 |
veterinary public | 42 |
general public | 42 |
five years | 42 |
cftr expression | 42 |
health risks | 42 |
former soviet | 42 |
adverse event | 42 |
contaminated water | 42 |
virulence factors | 41 |
may need | 41 |
economic growth | 41 |
aged years | 41 |
human infection | 41 |
central america | 41 |
blood samples | 41 |
nursing homes | 41 |
tract infection | 41 |
previously reported | 41 |
wild type | 41 |
raccoon rabies | 41 |
million cases | 41 |
better understand | 41 |
east asia | 41 |
adaptation strategies | 41 |
significantly reduced | 40 |
healthy people | 40 |
local health | 40 |
cftr gene | 40 |
fibrosis foundation | 40 |
epithelial cell | 40 |
two groups | 40 |
pediatric population | 40 |
common cold | 40 |
hemorrhagic fevers | 40 |
chagas disease | 40 |
year old | 40 |
last years | 40 |
hospitalized patients | 40 |
virus infections | 40 |
wild birds | 40 |
care centers | 40 |
national security | 40 |
preventive measures | 40 |
health impact | 40 |
venezuelan equine | 40 |
host range | 40 |
pathogenic avian | 40 |
signs include | 39 |
based precautions | 39 |
select agents | 39 |
situation report | 39 |
dairy cattle | 39 |
small number | 39 |
medical records | 39 |
population size | 39 |
recent studies | 39 |
older children | 39 |
three patients | 39 |
international organizations | 39 |
several years | 39 |
bacterial pathogens | 39 |
foreign policy | 39 |
health management | 39 |
national center | 39 |
high school | 39 |
also found | 39 |
health problem | 39 |
patients treated | 39 |
clinical studies | 39 |
among persons | 39 |
disease virus | 39 |
human airway | 39 |
hiv transmission | 39 |
retrospective study | 39 |
quality improvement | 39 |
physical activity | 39 |
sexually transmitted | 38 |
salmonella infection | 38 |
study group | 38 |
virus disease | 38 |
fever virus | 38 |
case series | 38 |
one year | 38 |
clinical microbiology | 38 |
first years | 38 |
federal agencies | 38 |
medical conditions | 38 |
care systems | 38 |
watery diarrhea | 38 |
vast majority | 38 |
cerebrospinal fluid | 38 |
research complications | 38 |
disaster reduction | 38 |
currently available | 38 |
must also | 38 |
old female | 38 |
many cases | 38 |
phylogenetic analysis | 38 |
borne disease | 38 |
also occur | 38 |
overall survival | 38 |
eastern europe | 38 |
tick paralysis | 38 |
disaster response | 38 |
per patient | 38 |
postexposure prophylaxis | 37 |
molecular epidemiology | 37 |
internationally adopted | 37 |
year period | 37 |
san francisco | 37 |
antiviral drugs | 37 |
readily available | 37 |
natural disaster | 37 |
ebola outbreak | 37 |
policy makers | 37 |
international trade | 37 |
findings suggest | 37 |
recent study | 37 |
every year | 37 |
lassa fever | 37 |
relatively low | 37 |
will help | 37 |
statistical analysis | 37 |
environmental factors | 37 |
health laboratories | 37 |
respiratory secretions | 37 |
million doses | 37 |
sequence data | 37 |
ca i | 37 |
infected individuals | 37 |
literature review | 37 |
surveillance data | 37 |
chronic disease | 37 |
secondary bacterial | 37 |
lyme borreliosis | 37 |
spongiform encephalopathy | 37 |
apical membrane | 37 |
phase i | 37 |
clinical symptoms | 37 |
time period | 37 |
risk groups | 37 |
much less | 37 |
terrorist attacks | 37 |
animal products | 36 |
vaccination programs | 36 |
present study | 36 |
children younger | 36 |
drug use | 36 |
family history | 36 |
significantly increased | 36 |
disease risk | 36 |
supply chain | 36 |
index case | 36 |
oxidative stress | 36 |
prevent transmission | 36 |
birth cohort | 36 |
tourism industry | 36 |
economic development | 36 |
body weight | 36 |
displaced persons | 36 |
healthcare providers | 36 |
global pandemic | 36 |
mean fev | 36 |
human milk | 36 |
real time | 36 |
genetic diversity | 36 |
many people | 36 |
cell count | 36 |
performed using | 36 |
previous studies | 36 |
medical treatment | 36 |
older persons | 36 |
much higher | 36 |
early stages | 36 |
small intestine | 36 |
care professionals | 36 |
cftr protein | 36 |
patients without | 35 |
haemorrhagic fever | 35 |
science policy | 35 |
blood products | 35 |
urinary tract | 35 |
nursing home | 35 |
hemolytic anemia | 35 |
mitigation strategies | 35 |
health emergency | 35 |
food allergy | 35 |
government agencies | 35 |
bacterial pneumonia | 35 |
birth weight | 35 |
clinical outcomes | 35 |
mechanical ventilation | 35 |
care units | 35 |
mass casualty | 35 |
many patients | 35 |
small ruminants | 35 |
made available | 35 |
population health | 35 |
mountain spotted | 35 |
great gatsby | 35 |
highly contagious | 35 |
fluorescent antibody | 35 |
median time | 35 |
tick bites | 35 |
clostridium perfringens | 35 |
several weeks | 35 |
pediatric hematology | 35 |
newcastle disease | 35 |
first months | 35 |
may contribute | 35 |
rotavirus vaccine | 34 |
retrospective review | 34 |
cancer patients | 34 |
mg dl | 34 |
hearing loss | 34 |
pediatric cancer | 34 |
another study | 34 |
nucleic acid | 34 |
chloride channel | 34 |
studies suggest | 34 |
differential diagnoses | 34 |
children aged | 34 |
chronic infection | 34 |
patients undergoing | 34 |
prospective studies | 34 |
western blot | 34 |
bovine spongiform | 34 |
three times | 34 |
urban areas | 34 |
iv antibiotics | 34 |
among patients | 34 |
blood pressure | 34 |
pneumococcal conjugate | 34 |
saudi arabia | 34 |
healthcare personnel | 34 |
circuit current | 34 |
universal access | 34 |
enteric pathogens | 34 |
care delivery | 34 |
zika virus | 34 |
zoonotic pathogens | 34 |
fatty acid | 33 |
persons aged | 33 |
young adult | 33 |
respiratory viruses | 33 |
rise buildings | 33 |
cold war | 33 |
cell proliferation | 33 |
meningococcal disease | 33 |
time pcr | 33 |
food production | 33 |
general assembly | 33 |
coronavirus pandemic | 33 |
humanitarian assistance | 33 |
health disparities | 33 |
previously described | 33 |
contact tracing | 33 |
single dose | 33 |
acute diarrhea | 33 |
vulnerable groups | 33 |
racial ethnic | 33 |
tick bite | 33 |
tested positive | 33 |
european commission | 33 |
viral infection | 33 |
population growth | 33 |
passive immunity | 33 |
rift valley | 33 |
phase ii | 33 |
animal rabies | 33 |
food animals | 33 |
distress syndrome | 33 |
chemical agents | 33 |
usually occurs | 33 |
ill patients | 33 |
care services | 33 |
cell transplant | 33 |
hiv prevention | 32 |
president trump | 32 |
cftr function | 32 |
preliminary results | 32 |
pharmaceutical companies | 32 |
diagnostic tests | 32 |
immunization schedule | 32 |
human bronchial | 32 |
etiologic agent | 32 |
pertussis vaccine | 32 |
based surveillance | 32 |
case definition | 32 |
several months | 32 |
virus vaccines | 32 |
valley fever | 32 |
acquired infections | 32 |
three years | 32 |
vector control | 32 |
respiratory pathogens | 32 |
viral hepatitis | 32 |
international health | 32 |
genome sequencing | 32 |
lymph node | 32 |
dengue fever | 32 |
health issues | 32 |
infected patients | 32 |
costs associated | 32 |
patient population | 32 |
logistic regression | 32 |
neonatal intensive | 32 |
infected children | 32 |
transmembrane conductance | 32 |
affected areas | 32 |
control programs | 32 |
future research | 32 |
will become | 32 |
influenza vaccination | 32 |
clinical syndromes | 32 |
well tolerated | 32 |
blood culture | 32 |
data collected | 32 |
acute infection | 31 |
intestinal tract | 31 |
human populations | 31 |
sex workers | 31 |
foodborne illness | 31 |
cell transplantation | 31 |
health agencies | 31 |
disease emergence | 31 |
factor viii | 31 |
polio vaccine | 31 |
international community | 31 |
pulmonary edema | 31 |
us population | 31 |
new technologies | 31 |
conductance regulator | 31 |
backyard birds | 31 |
respiratory infection | 31 |
avian flu | 31 |
syndrome coronavirus | 31 |
erythema migrans | 31 |
electron microscopy | 31 |
surface liquid | 31 |
medically important | 31 |
several studies | 31 |
rna viruses | 31 |
health risk | 31 |
cftr activity | 31 |
bloodstream infections | 31 |
domestic dogs | 31 |
six months | 31 |
associated diarrhea | 31 |
health department | 31 |
prevention strategies | 31 |
surge capacity | 31 |
chronic hepatitis | 31 |
developed world | 31 |
evidence suggests | 31 |
informed consent | 31 |
emergency medicine | 31 |
environmental contamination | 31 |
death rates | 31 |
past decade | 30 |
service providers | 30 |
also provides | 30 |
animal production | 30 |
motor performance | 30 |
airway inflammation | 30 |
pediatric patient | 30 |
socioeconomic status | 30 |
will provide | 30 |
weight gain | 30 |
took place | 30 |
flow cytometry | 30 |
disaster preparedness | 30 |
clinically significant | 30 |
renewable energy | 30 |
people living | 30 |
hypertonic saline | 30 |
close contacts | 30 |
fire protection | 30 |
vaccine candidates | 30 |
travel restrictions | 30 |
community health | 30 |
virus transmission | 30 |
chest radiograph | 30 |
new jersey | 30 |
ecosystem services | 30 |
healthy adults | 30 |
better understanding | 30 |
stress disorder | 30 |
transplant recipients | 30 |
listeria monocytogenes | 30 |
relapsing fever | 30 |
antibody titers | 30 |
psychological trauma | 30 |
myeloid leukemia | 30 |
infection rates | 30 |
cancer survivors | 30 |
i sc | 30 |
two decades | 30 |
best practices | 30 |
months old | 29 |
social security | 29 |
one hand | 29 |
cholera toxin | 29 |
month period | 29 |
salmonella typhimurium | 29 |
hospital admission | 29 |
also cause | 29 |
yersinia pestis | 29 |
clinical characteristics | 29 |
attack rate | 29 |
patients aged | 29 |
sputum samples | 29 |
monitoring systems | 29 |
linked immunosorbent | 29 |
among adults | 29 |
vaccine industry | 29 |
first reported | 29 |
across countries | 29 |
animal species | 29 |
many parts | 29 |
ixodes scapularis | 29 |
solid tumors | 29 |
pneumonic plague | 29 |
results indicate | 29 |
medical record | 29 |
examples include | 29 |
may affect | 29 |
case study | 29 |
four patients | 29 |
asl volume | 29 |
pg ml | 29 |
first described | 29 |
one third | 29 |
medical school | 29 |
per million | 29 |
immunosorbent assay | 29 |
muc ac | 29 |
every hours | 29 |
variational inequality | 29 |
information systems | 29 |
fatality rates | 29 |
management practices | 29 |
metabolic acidosis | 29 |
wild animal | 29 |
pilot study | 29 |
transmission occurs | 29 |
viral diarrhea | 29 |
body mass | 28 |
asthma prevalence | 28 |
skin test | 28 |
drug resistance | 28 |
training programs | 28 |
north carolina | 28 |
child care | 28 |
analysis revealed | 28 |
among infants | 28 |
high level | 28 |
standard deviation | 28 |
infectious bovine | 28 |
local public | 28 |
hiv status | 28 |
clinical laboratory | 28 |
nerve agent | 28 |
botulinum toxin | 28 |
resistant enterococci | 28 |
western countries | 28 |
japanese encephalitis | 28 |
new world | 28 |
new vaccine | 28 |
germ warfare | 28 |
air quality | 28 |
airway epithelium | 28 |
mucociliary clearance | 28 |
sars outbreak | 28 |
household members | 28 |
active surveillance | 28 |
posttraumatic stress | 28 |
taken together | 28 |
viral load | 28 |
fibrosis transmembrane | 28 |
human migration | 28 |
federal funding | 28 |
day care | 28 |
population dynamics | 28 |
food supply | 28 |
universal precautions | 28 |
limited number | 28 |
potential risk | 28 |
significantly different | 28 |
environmental protection | 28 |
skin lesions | 28 |
high fever | 28 |
infections among | 28 |
different types | 28 |
within months | 28 |
sri lanka | 28 |
seasonal influenza | 28 |
hematology oncology | 28 |
perceived threat | 28 |
confirmed covid | 28 |
control study | 28 |
two cases | 28 |
many different | 28 |
fibrosis patients | 28 |
several days | 28 |
barr virus | 27 |
vaccine administered | 27 |
iron overload | 27 |
medical personnel | 27 |
viral diseases | 27 |
human beings | 27 |
see also | 27 |
security council | 27 |
acute care | 27 |
months later | 27 |
may produce | 27 |
surgeon general | 27 |
nocturnal enuresis | 27 |
million persons | 27 |
enteric viruses | 27 |
feral cat | 27 |
eye protection | 27 |
preventive services | 27 |
western europe | 27 |
infection among | 27 |
sudden death | 27 |
hodgkin lymphoma | 27 |
medical research | 27 |
increasing number | 27 |
living systems | 27 |
include fever | 27 |
human influenza | 27 |
active shooter | 27 |
risk perception | 27 |
endangered species | 27 |
will occur | 27 |
diseases caused | 27 |
acute myeloid | 27 |
may vary | 27 |
health programs | 27 |
oral route | 27 |
scientific community | 27 |
type cftr | 27 |
results show | 27 |
contact precautions | 27 |
data analysis | 27 |
producing animals | 27 |
serologic tests | 27 |
well documented | 27 |
york times | 27 |
technical assistance | 27 |
early childhood | 27 |
basic research | 27 |
healthcare settings | 27 |
particularly important | 27 |
carbon dioxide | 27 |
days later | 27 |
effective treatment | 27 |
key role | 27 |
highly infectious | 27 |
study population | 27 |
less frequently | 26 |
us government | 26 |
nerve agents | 26 |
neutralizing antibodies | 26 |
new england | 26 |
liberal order | 26 |
vaccinia virus | 26 |
higher levels | 26 |
findings include | 26 |
intervention studies | 26 |
cell counts | 26 |
emergency preparedness | 26 |
resistant strains | 26 |
health infrastructure | 26 |
human infections | 26 |
clinic visits | 26 |
infection transmission | 26 |
domestic animal | 26 |
high degree | 26 |
bovine viral | 26 |
significantly associated | 26 |
research center | 26 |
case reports | 26 |
primary prevention | 26 |
stool cultures | 26 |
bloody diarrhea | 26 |
ion transport | 26 |
infections may | 26 |
newborn screening | 26 |
first step | 26 |
disease among | 26 |
respiratory diseases | 26 |
febrile illness | 26 |
also associated | 26 |
risk perceptions | 26 |
highest risk | 26 |
may play | 26 |
treatment plans | 26 |
significant risk | 26 |
wildlife interface | 26 |
chapel hill | 26 |
infection occurs | 26 |
armed conflict | 26 |
clinical specimens | 26 |
linear regression | 26 |
less effective | 26 |
trypanosoma cruzi | 26 |
diabetes mellitus | 26 |
health concerns | 26 |
clinical care | 26 |
food insecurity | 26 |
air travel | 26 |
smallpox vaccine | 26 |
human pathogens | 26 |
bronchoalveolar lavage | 26 |
shiga toxin | 26 |
respiratory illnesses | 26 |
cell death | 26 |
ionizing radiation | 26 |
relatively high | 26 |
significantly decreased | 26 |
resistant bacteria | 26 |
will allow | 26 |
epidemic diarrhea | 26 |
blood transfusions | 26 |
social support | 26 |
food animal | 26 |
inclusion criteria | 26 |
nl min | 26 |
antibody response | 26 |
health workers | 26 |
prevention interventions | 26 |
gram negative | 26 |
small molecule | 26 |
elderly persons | 26 |
mg ml | 26 |
weapons convention | 26 |
may take | 26 |
low risk | 26 |
immune globulin | 26 |
affected countries | 25 |
borne infectious | 25 |
effective vaccine | 25 |
within weeks | 25 |
international institutions | 25 |
response rate | 25 |
twentieth century | 25 |
healthy controls | 25 |
scientific research | 25 |
medical management | 25 |
state health | 25 |
puerto rico | 25 |
phylodynamic methods | 25 |
anthrax spores | 25 |
high commissioner | 25 |
un agencies | 25 |
herpes simplex | 25 |
channel activity | 25 |
medical services | 25 |
animal feed | 25 |
cases occur | 25 |
global scale | 25 |
viral gastroenteritis | 25 |
will often | 25 |
increasingly important | 25 |
supreme court | 25 |
like illness | 25 |
significant changes | 25 |
depression symptoms | 25 |
chronic lyme | 25 |
indirect contact | 25 |
land use | 25 |
poor countries | 25 |
white house | 25 |
aedes aegypti | 25 |
healthy children | 25 |
tissue culture | 25 |
resistant organisms | 25 |
cause severe | 25 |
backyard farming | 25 |
chronic diarrhea | 25 |
francisella tularensis | 25 |
early detection | 25 |
year post | 25 |
risk communication | 25 |
significant decrease | 25 |
high dose | 25 |
began shooting | 25 |
influenzae type | 25 |
disease burden | 25 |
respiratory protection | 25 |
atp release | 25 |
primary infection | 25 |
older age | 25 |
donald trump | 25 |
foreign aid | 25 |
natural resources | 25 |
disease threats | 25 |
invasive species | 25 |
affected area | 25 |
occupational safety | 25 |
acute chest | 25 |
pandemic response | 25 |
cases occurred | 25 |
east respiratory | 25 |
microbial threats | 24 |
porcine epidemic | 24 |
southwestern united | 24 |
hantavirus pulmonary | 24 |
chronic lung | 24 |
gel electrophoresis | 24 |
allergic disease | 24 |
often associated | 24 |
host defense | 24 |
american association | 24 |
chinese government | 24 |
medical response | 24 |
per person | 24 |
health response | 24 |
global warming | 24 |
anxiety symptoms | 24 |
cancer treatment | 24 |
also included | 24 |
disease research | 24 |
medical history | 24 |
usually associated | 24 |
blood safety | 24 |
change adaptation | 24 |
viral respiratory | 24 |
radiation therapy | 24 |
ct scan | 24 |
occupational health | 24 |
one example | 24 |
therapy may | 24 |
emerging disease | 24 |
may increase | 24 |
health needs | 24 |
may represent | 24 |
civil society | 24 |
chest syndrome | 24 |
depressive symptoms | 24 |
leading causes | 24 |
poor prognosis | 24 |
middle ear | 24 |
large scale | 24 |
preventing transmission | 24 |
wildlife health | 24 |
african countries | 24 |
salmonella infections | 24 |
approximately one | 24 |
adverse reactions | 24 |
sweat chloride | 24 |
definitive diagnosis | 24 |
first recognized | 24 |
virus may | 24 |
environmental conditions | 24 |
west bengal | 24 |
immunization program | 24 |
antiretroviral therapy | 24 |
health measures | 24 |
bovine rhinotracheitis | 24 |
well understood | 24 |
deaths per | 24 |
personal hygiene | 24 |
annual report | 24 |
hepatocellular carcinoma | 24 |
medical attention | 24 |
economic impacts | 24 |
action plan | 24 |
uremic syndrome | 24 |
preventive medicine | 24 |
cells expressing | 24 |
generation sequencing | 24 |
exponential growth | 24 |
team members | 24 |
vaccine adverse | 24 |
patients diagnosed | 24 |
marrow failure | 24 |
statistical significance | 24 |
production systems | 24 |
campylobacter enteritis | 24 |
natural infection | 24 |
healthy individuals | 24 |
health education | 24 |
pulmonary syndrome | 24 |
national governments | 24 |
billion people | 24 |
cardiovascular disease | 24 |
three months | 24 |
will increase | 24 |
practices advisory | 24 |
microscopic examination | 24 |
health information | 24 |
temporary protection | 24 |
data show | 24 |
old children | 23 |
social services | 23 |
prime minister | 23 |
organ transplantation | 23 |
ml kg | 23 |
diarrheal diseases | 23 |
pulmonary infection | 23 |
environmental samples | 23 |
fold increase | 23 |
broad range | 23 |
common source | 23 |
hand washing | 23 |
submucosal glands | 23 |
clinical cases | 23 |
first century | 23 |
care setting | 23 |
salmonella spp | 23 |
infect dis | 23 |
may reduce | 23 |
disease progression | 23 |
widespread use | 23 |
human transmission | 23 |
future studies | 23 |
backyard chickens | 23 |
clinical data | 23 |
death rate | 23 |
pleural effusions | 23 |
chronically infected | 23 |
wound infections | 23 |
viral disease | 23 |
critical role | 23 |
environmental surfaces | 23 |
randomized trial | 23 |
asl height | 23 |
social science | 23 |
air traffic | 23 |
airway obstruction | 23 |
clinical diagnosis | 23 |
least two | 23 |
chest radiography | 23 |
protein expression | 23 |
common causes | 23 |
chronic liver | 23 |
endemic area | 23 |
shock syndrome | 23 |
two weeks | 23 |
time points | 23 |
will develop | 23 |
pericardial effusion | 23 |
liver biopsy | 23 |
proactive coping | 23 |
times higher | 23 |
vaccine production | 23 |
herpes zoster | 23 |
antibiotics may | 23 |
times daily | 23 |
low cost | 23 |
serologic testing | 23 |
first cases | 23 |
living conditions | 23 |
may remain | 23 |
healthcare professionals | 23 |
transmitted diseases | 23 |
diagnostic laboratory | 23 |
national level | 23 |
transfusion transmission | 23 |
live attenuated | 23 |
pcr assay | 23 |
infected infants | 23 |
black disease | 23 |
stem cells | 23 |
endoplasmic reticulum | 23 |
clinical management | 23 |
human papillomavirus | 23 |
information regarding | 23 |
high incidence | 23 |
emerging zoonoses | 23 |
current study | 23 |
cause serious | 23 |
may offer | 23 |
whole blood | 23 |
often used | 23 |
contagious ecthyma | 23 |
safety monitoring | 23 |
sample size | 23 |
one case | 23 |
food aid | 23 |
environmental degradation | 23 |
study conducted | 23 |
several countries | 22 |
first week | 22 |
personal protection | 22 |
develop new | 22 |
sars coronavirus | 22 |
health program | 22 |
fungal infections | 22 |
humanitarian aid | 22 |
passive surveillance | 22 |
managed care | 22 |
copyright holder | 22 |
virus causes | 22 |
also reported | 22 |
health effects | 22 |
radiographic features | 22 |
supply chains | 22 |
coverage among | 22 |
laboratory findings | 22 |
diseases may | 22 |
pet food | 22 |
norwalk virus | 22 |
uenza pandemic | 22 |
congenital heart | 22 |
disseminated intravascular | 22 |
large animal | 22 |
lower levels | 22 |
laboratory tests | 22 |
varicella vaccine | 22 |
rapidly evolving | 22 |
higher education | 22 |
immunization programs | 22 |
initial infection | 22 |
ad hoc | 22 |
short period | 22 |
labour platforms | 22 |
executive order | 22 |
enteric disease | 22 |
north korea | 22 |
young people | 22 |
randomized controlled | 22 |
acellular pertussis | 22 |
sexual orientation | 22 |
host disease | 22 |
mucous membrane | 22 |
sectional study | 22 |
ghg emissions | 22 |
regression models | 22 |
diagnosed asthma | 22 |
gates foundation | 22 |
prairie dogs | 22 |
international airport | 22 |
infection prevention | 22 |
blood loss | 22 |
case studies | 22 |
gold standard | 22 |
higher rates | 22 |
machine readable | 22 |
paraquat poisoning | 22 |
organ systems | 22 |
intravenous drug | 22 |
sequence analysis | 22 |
two different | 22 |
labour markets | 22 |
gene transfer | 22 |
many areas | 22 |
health crisis | 22 |
based study | 22 |
cell types | 22 |
home orders | 22 |
water quality | 22 |
host species | 22 |
monoclonal antibody | 22 |
important cause | 22 |
acute gastroenteritis | 22 |
previous months | 22 |
susceptible individuals | 22 |
innate immune | 22 |
vesicular stomatitis | 22 |
national park | 22 |
cat populations | 22 |
local level | 22 |
personal communication | 22 |
will lead | 22 |
measured using | 22 |
painted toys | 22 |
also increased | 22 |
treatment options | 22 |
death toll | 22 |
one another | 22 |
pcr assays | 22 |
million deaths | 22 |
research institute | 22 |
newly emerging | 22 |
safety concerns | 22 |
prevalence rates | 22 |
severely affected | 22 |
health coverage | 22 |
human medicine | 22 |
highly effective | 22 |
burkholderia cepacia | 22 |
survival rates | 22 |
radiation exposure | 22 |
diagnostic testing | 22 |
acute phase | 21 |
quality control | 21 |
methyl bromide | 21 |
see additional | 21 |
nonhuman primates | 21 |
healthcare system | 21 |
iii trials | 21 |
pandemic will | 21 |
fluid secretion | 21 |
frequently associated | 21 |
platelet counts | 21 |
two major | 21 |
metastatic disease | 21 |
virus isolation | 21 |
mask wearing | 21 |
previously shown | 21 |
infection risk | 21 |
host cell | 21 |
chronic inflammation | 21 |
nuclear weapons | 21 |
current order | 21 |
major role | 21 |
different species | 21 |
global economy | 21 |
black death | 21 |
million per | 21 |
large quantities | 21 |
next generation | 21 |
borne encephalitis | 21 |
early diagnosis | 21 |
domestic poultry | 21 |
treatment group | 21 |
lung injury | 21 |
reported among | 21 |
many factors | 21 |
water supply | 21 |
ct scans | 21 |
high rate | 21 |
infectious diarrhea | 21 |
clinical samples | 21 |
biological attack | 21 |
chemical warfare | 21 |
attack rates | 21 |
negative bacilli | 21 |
reproductive health | 21 |
hsct patients | 21 |
us public | 21 |
lesions include | 21 |
civil aviation | 21 |
variant creutzfeldt | 21 |
infants born | 21 |
modified live | 21 |
nosocomial infection | 21 |
data available | 21 |
yersinia enterocolitica | 21 |
war i | 21 |
nk cells | 21 |
emergency medical | 21 |
economic losses | 21 |
hate crimes | 21 |
origin node | 21 |
two months | 21 |
fever viruses | 21 |
mental status | 21 |
made disasters | 21 |
health concern | 21 |
exome sequencing | 21 |
rotavirus infections | 21 |
human diseases | 21 |
transmission dynamics | 21 |
protection agency | 21 |
mass index | 21 |
surface antigen | 21 |
rabies vaccine | 21 |
klebsiella pneumoniae | 21 |
care center | 21 |
practice guidelines | 21 |
animal model | 21 |
cell cultures | 21 |
mediated immunity | 21 |
mass spectrometry | 21 |
patient developed | 21 |
biofilm formation | 21 |
granted medrxiv | 21 |
international development | 21 |
patients admitted | 21 |
estimated million | 21 |
first weeks | 21 |
vibrio cholerae | 21 |
bite wounds | 21 |
vaccine supply | 21 |
energy consumption | 21 |
gastrostomy tube | 21 |
young animals | 21 |
health implications | 21 |
surface expression | 21 |
anthrax attacks | 21 |
costa rica | 21 |
vaccine research | 21 |
mycobacterium bovis | 21 |
chest pain | 21 |
patients will | 21 |
genetically modified | 21 |
fire alarm | 21 |
older animals | 21 |
occupational exposure | 21 |
droplet precautions | 21 |
last decade | 21 |
almost always | 21 |
author funder | 21 |
online survey | 21 |
beta toxin | 21 |
chronic obstructive | 21 |
peer review | 21 |
first three | 21 |
vaccine series | 21 |
lung transplant | 21 |
scientific evidence | 21 |
pancreatic insufficiency | 21 |
although many | 21 |
state university | 21 |
negative bacteria | 21 |
among people | 21 |
na absorption | 21 |
gene segments | 21 |
total population | 21 |
red cell | 21 |
patients developed | 21 |
antimicrobial drugs | 21 |
care provider | 21 |
significant impact | 21 |
crucial role | 20 |
mitigation measures | 20 |
early recognition | 20 |
immune status | 20 |
severe anemia | 20 |
two doses | 20 |
may appear | 20 |
cases may | 20 |
protective immunity | 20 |
sore throat | 20 |
strongly agree | 20 |
continuing professional | 20 |
similar results | 20 |
type iii | 20 |
following section | 20 |
great britain | 20 |
second world | 20 |
observational studies | 20 |
cftr trafficking | 20 |
year follow | 20 |
older people | 20 |
dna nanoparticles | 20 |
cftr mutations | 20 |
reservoir hosts | 20 |
three countries | 20 |
new therapies | 20 |
cryptosporidium parvum | 20 |
research council | 20 |
severe illness | 20 |
clinical laboratories | 20 |
protective clothing | 20 |
hospital medical | 20 |
chicken pox | 20 |
induced sputum | 20 |
prevention science | 20 |
passive transfer | 20 |
viral pathogens | 20 |
cam therapies | 20 |
fecal leukocytes | 20 |
vertical transmission | 20 |
provides information | 20 |
food preparation | 20 |
immunization safety | 20 |
disease occurs | 20 |
goat kids | 20 |
maintenance therapy | 20 |
related diabetes | 20 |
young infants | 20 |
final report | 20 |
natural reservoir | 20 |
effective response | 20 |
avian species | 20 |
new infections | 20 |
commonly associated | 20 |
first hours | 20 |
retrospective cohort | 20 |
crisis management | 20 |
symptoms may | 20 |
significant number | 20 |
long time | 20 |
negative effects | 20 |
hcv infection | 20 |
leukemia virus | 20 |
body composition | 20 |
supplementary material | 20 |
chronic conditions | 20 |
animal agriculture | 20 |
control strategies | 20 |
studies using | 20 |
may reflect | 20 |
influenza vaccines | 20 |
environmental change | 20 |
fluid therapy | 20 |
clinical picture | 20 |
prevention measures | 20 |
foodborne disease | 20 |
american college | 20 |
family member | 20 |
pneumococcal disease | 20 |
children ages | 20 |
face masks | 20 |
pharmaceutical industry | 20 |
potential therapeutic | 20 |
nations international | 20 |
far less | 20 |
provide information | 20 |
liver enzymes | 20 |
entry screening | 20 |
rsv infection | 20 |
national academy | 20 |
capacity building | 20 |
large part | 20 |
major public | 20 |
medical staff | 20 |
central venous | 20 |
response efforts | 20 |
bibliometric analysis | 20 |
pet ct | 20 |
studies indicate | 20 |
inspection service | 20 |
induction therapy | 20 |
electronic medical | 20 |
patients infected | 20 |
mesenteric lymph | 20 |
opportunistic infections | 20 |
hbv infection | 20 |
first dose | 20 |
strains isolated | 20 |
occurs within | 20 |
also include | 20 |
abortion care | 20 |
world food | 20 |
geographic location | 20 |
amblyomma americanum | 20 |
wilms tumor | 20 |
poorly understood | 20 |
health interventions | 20 |
developing nations | 20 |
version posted | 20 |
significant association | 20 |
transmission cycle | 19 |
borne viruses | 19 |
mosquito vectors | 19 |
one week | 19 |
newborn infant | 19 |
hurricane katrina | 19 |
extreme weather | 19 |
network equilibrium | 19 |
pediatric travelers | 19 |
high rates | 19 |
control subjects | 19 |
molecular biology | 19 |
per hour | 19 |
observational study | 19 |
contagious disease | 19 |
neurologic disease | 19 |
race ethnicity | 19 |
acupuncture treatment | 19 |
help prevent | 19 |
acute hepatitis | 19 |
study showed | 19 |
descriptive statistics | 19 |
infectious dose | 19 |
additional information | 19 |
potential difference | 19 |
vaccination rates | 19 |
first identified | 19 |
body condition | 19 |
significant reduction | 19 |
much lower | 19 |
cancer therapy | 19 |
issues related | 19 |
public awareness | 19 |
volcanic eruptions | 19 |
immunization coverage | 19 |
intestinal mucosa | 19 |
international law | 19 |
higher incidence | 19 |
cow disease | 19 |
hygiene education | 19 |
injection drug | 19 |
diseases society | 19 |
clinically stable | 19 |
screening tests | 19 |
among health | 19 |
new diseases | 19 |
vaccine effectiveness | 19 |
patient outcomes | 19 |
infection rate | 19 |
coxiella burnetii | 19 |
droplet nuclei | 19 |
bubonic plague | 19 |
first days | 19 |
ophthalmic emergencies | 19 |
live animal | 19 |
may show | 19 |
diagnostic laboratories | 19 |
samples collected | 19 |
heart failure | 19 |
coronavirus outbreak | 19 |
risk areas | 19 |
body temperature | 19 |
oral rehydration | 19 |
care costs | 19 |
emergency assistance | 19 |
vascular malformations | 19 |
democratic republic | 19 |
infected people | 19 |
severe respiratory | 19 |
supportive therapy | 19 |
ethnic groups | 19 |
surveillance program | 19 |
vaccine coverage | 19 |
animal welfare | 19 |
data set | 19 |
vaccine manufacturers | 19 |
clinical research | 19 |
major concern | 19 |
airborne precautions | 19 |
modifier genes | 19 |
children living | 19 |
small bowel | 19 |
lower lobes | 19 |
blood smears | 19 |
early stage | 19 |
swine industry | 19 |
emergency departments | 19 |
person spread | 19 |
hospital care | 19 |
positive blood | 19 |
human granulocytic | 19 |
low temperature | 19 |
local authorities | 19 |
tsunami warning | 19 |
cancer care | 19 |
clinical outcome | 19 |
enteric infections | 19 |
marrow transplantation | 19 |
billion per | 19 |
significantly less | 19 |
medical equipment | 19 |
gene segment | 19 |
livestock production | 19 |
research team | 19 |
longitudinal study | 19 |
factors affecting | 19 |
directly related | 19 |
ebola transmission | 19 |
terrorist groups | 19 |
mouse model | 19 |
health surveillance | 19 |
also identified | 19 |
human rotavirus | 19 |
one time | 19 |
relatively small | 19 |
antibody responses | 19 |
routine use | 19 |
incidence rates | 19 |
environmental health | 19 |
national immunization | 19 |
veterinary medical | 19 |
two distinct | 19 |
american red | 19 |
transcription factor | 19 |
biological threats | 19 |
financial support | 19 |
nosocomial transmission | 19 |
acquired immunodeficiency | 19 |
cultural property | 19 |
selective pressure | 19 |
prevention recommendations | 19 |
global burden | 19 |
live vaccines | 19 |
surgical resection | 19 |
hospital admissions | 19 |
grade fever | 19 |
global climate | 19 |
biotic impoverishment | 19 |
eastern equine | 19 |
medical education | 19 |
otherwise healthy | 19 |
local governments | 19 |
preliminary data | 19 |
united way | 19 |
common clinical | 19 |
widely available | 19 |
economic consequences | 19 |
short circuit | 19 |
disease spread | 19 |
university hospital | 19 |
sexual exploitation | 19 |
overall health | 19 |
risk patients | 19 |
many states | 19 |
exit screening | 19 |
average age | 19 |
laboratory testing | 19 |
second dose | 19 |
trump administration | 19 |
specific treatment | 19 |
income inequality | 19 |
sex work | 19 |
swine influenza | 19 |
cough etiquette | 19 |
human metapneumovirus | 19 |
lockdown measures | 19 |
pulmonary tuberculosis | 19 |
iu kg | 18 |
vod sos | 18 |
related deaths | 18 |
large outbreaks | 18 |
infections caused | 18 |
old world | 18 |
infected animal | 18 |
food poisoning | 18 |
many developing | 18 |
medical countermeasures | 18 |
major risk | 18 |
direito penal | 18 |
mg day | 18 |
care personnel | 18 |
younger animals | 18 |
serum antibody | 18 |
gestational age | 18 |
public transportation | 18 |
contaminated dog | 18 |
occur within | 18 |
state public | 18 |
provide additional | 18 |
autosomal recessive | 18 |
may benefit | 18 |
health inequalities | 18 |
outpatient visits | 18 |
near future | 18 |
blood flow | 18 |
genes involved | 18 |
assessed using | 18 |
medical condition | 18 |
potential exposure | 18 |
like viruses | 18 |
also available | 18 |
symptoms include | 18 |
foreign animal | 18 |
significant effect | 18 |
global public | 18 |
two main | 18 |
national survey | 18 |
necrotizing enterocolitis | 18 |
health emergencies | 18 |
hygiene procedures | 18 |
first line | 18 |
live virus | 18 |
internally displaced | 18 |
social isolation | 18 |
swine flu | 18 |
helicobacter pylori | 18 |
south american | 18 |
new disease | 18 |
frequently used | 18 |
childhood immunization | 18 |
cepacia complex | 18 |
hemolytic uremic | 18 |
like virus | 18 |
also important | 18 |
lower risk | 18 |
short term | 18 |
economic models | 18 |
community transmission | 18 |
air force | 18 |
refugee migration | 18 |
acute renal | 18 |
stool specimens | 18 |
much greater | 18 |
marrow transplant | 18 |
male patients | 18 |
potential role | 18 |
pathogen transmission | 18 |
million children | 18 |
intravascular coagulation | 18 |
respiratory droplets | 18 |
analyzed using | 18 |
analysis showed | 18 |
mononuclear cells | 18 |
resistance genes | 18 |
virus type | 18 |
hyperactivity disorder | 18 |
septic shock | 18 |
different levels | 18 |
highly variable | 18 |
enteroaggregative escherichia | 18 |
important factor | 18 |
health sector | 18 |
cohort studies | 18 |
heart rate | 18 |
indian ocean | 18 |
every day | 18 |
large proportion | 18 |
study demonstrated | 18 |
secondary transmission | 18 |
health challenges | 18 |
strongly associated | 18 |
health security | 18 |
reporting system | 18 |
susceptible persons | 18 |
immunization policy | 18 |
may last | 18 |
mortality among | 18 |
international organization | 18 |
vaccine strains | 18 |
bacterial meningitis | 18 |
agents may | 18 |
antimicrobial use | 18 |
insurance coverage | 18 |
large outbreak | 18 |
blood supply | 18 |
research topics | 18 |
approximately million | 18 |
least days | 18 |
rotavirus diarrhea | 18 |
viral haemorrhagic | 18 |
wildlife disease | 18 |
clinical presentations | 18 |
hpv vaccine | 18 |
acute bronchitis | 18 |
liver failure | 18 |
new era | 18 |
cattle fever | 18 |
plant species | 18 |
among others | 18 |
western united | 18 |
veterinary services | 18 |
child health | 18 |
occurred among | 18 |
delivery systems | 18 |
significant improvements | 18 |
extremely rare | 18 |
virus spread | 18 |
international tourism | 18 |
medication abortion | 18 |
bcg vaccine | 18 |
less commonly | 18 |
african americans | 18 |
rapid response | 18 |
first wave | 18 |
northeastern united | 18 |
contact surfaces | 18 |
controlled study | 18 |
associated infections | 18 |
five patients | 18 |
function tests | 18 |
whole exome | 18 |
fever vaccine | 18 |
american society | 18 |
immunodeficiency syndrome | 18 |
johns hopkins | 18 |
hendra virus | 18 |
side effect | 18 |
influenza season | 18 |
health regulations | 18 |
early treatment | 18 |
economic sanctions | 18 |
zoster virus | 18 |
study reported | 18 |
wildlife populations | 18 |
common among | 18 |
intermediate hosts | 18 |
individuals may | 17 |
prion diseases | 17 |
life safety | 17 |
cancer diagnosis | 17 |
three major | 17 |
coronavirus cases | 17 |
least months | 17 |
identify potential | 17 |
virus particles | 17 |
rubella vaccine | 17 |
nine patients | 17 |
study found | 17 |
past two | 17 |
room temperature | 17 |
physical health | 17 |
multiple sclerosis | 17 |
resistant salmonella | 17 |
epidemiologic investigation | 17 |
either directly | 17 |
will remain | 17 |
brain tumors | 17 |
lesions may | 17 |
active disease | 17 |
fmd outbreak | 17 |
liquid interface | 17 |
transmissible spongiform | 17 |
home health | 17 |
malignant edema | 17 |
international standards | 17 |
clinical study | 17 |
building codes | 17 |
heat waves | 17 |
neutrophil count | 17 |
several hundred | 17 |
intravenous antibiotics | 17 |
many others | 17 |
mortality weekly | 17 |
exposed persons | 17 |
local government | 17 |
public policy | 17 |
became ill | 17 |
cftr chloride | 17 |
medical students | 17 |
new influenza | 17 |
well known | 17 |
important factors | 17 |
local transmission | 17 |
foodborne pathogens | 17 |
hiv infections | 17 |
long run | 17 |
recent report | 17 |
takes place | 17 |
international guidelines | 17 |
staff members | 17 |
diagnostic test | 17 |
chikungunya virus | 17 |
washington state | 17 |
available data | 17 |
growth rates | 17 |
rates among | 17 |
greatest risk | 17 |
immune deficiency | 17 |
health consequences | 17 |
healthcare facilities | 17 |
poor health | 17 |
research agenda | 17 |
ten years | 17 |
health threat | 17 |
affected populations | 17 |
first world | 17 |
higher scores | 17 |
national research | 17 |
pharmaceutical interventions | 17 |
civil war | 17 |
syndromic surveillance | 17 |
every months | 17 |
human activities | 17 |
unpasteurized milk | 17 |
six patients | 17 |
fecal contamination | 17 |
dominican republic | 17 |
occupational exposures | 17 |
low birth | 17 |
gastrointestinal symptoms | 17 |
asylum seekers | 17 |
data regarding | 17 |
political instability | 17 |
study design | 17 |
several decades | 17 |
wear gloves | 17 |
synthetic biology | 17 |
first two | 17 |
two types | 17 |
international cooperation | 17 |
directed toward | 17 |
recent outbreaks | 17 |
cause acute | 17 |
may pose | 17 |
threat posed | 17 |
among pediatric | 17 |
oncology physicians | 17 |
significantly greater | 17 |
results demonstrate | 17 |
measles vaccine | 17 |
systemic disease | 17 |
mortality associated | 17 |
secondary infection | 17 |
premature infants | 17 |
social determinants | 17 |
protective effect | 17 |
infantile diarrhea | 17 |
inflammatory markers | 17 |
study suggests | 17 |
cervical cancer | 17 |
will reduce | 17 |
health threats | 17 |
medical examination | 17 |
study aimed | 17 |
phylodynamic models | 17 |
another important | 17 |
relative humidity | 17 |
molecular surveillance | 17 |
neonatal diarrhea | 17 |
prevalence rate | 17 |
single case | 17 |
airway responsiveness | 17 |
percent change | 17 |
making process | 17 |
diarrhea may | 17 |
southern africa | 17 |
newborn infants | 17 |
acquired infection | 17 |
symptom onset | 17 |
forced expiratory | 17 |
control efforts | 17 |
will take | 17 |
integral part | 17 |
south asia | 17 |
states will | 17 |
longer term | 17 |
response strategies | 17 |
among young | 17 |
controlled trials | 17 |
respiratory signs | 17 |
treatment plan | 17 |
female sex | 17 |
inactivated vaccines | 17 |
international travelers | 17 |
shortly thereafter | 17 |
much larger | 17 |
von willebrand | 17 |
based approach | 17 |
surgical procedures | 17 |
racial disparities | 17 |
diagnostic methods | 17 |
renal function | 17 |
ewing sarcoma | 17 |
melinda gates | 17 |
limited data | 17 |
sulfuryl fluoride | 17 |
whole genome | 17 |
last two | 17 |
brain injury | 17 |
rate among | 17 |
mass media | 17 |
new antibiotics | 17 |
protein synthesis | 17 |
children may | 17 |
project teams | 17 |
water sources | 17 |
first isolated | 17 |
generation cephalosporins | 17 |
hbe cells | 17 |
also called | 17 |
provide protection | 17 |
agent orange | 17 |
per milliliter | 17 |
neutrophil elastase | 17 |
health conditions | 17 |
tetanus toxoid | 16 |
wearing masks | 16 |
old woman | 16 |
risk populations | 16 |
carrier animals | 16 |
authors declare | 16 |
wbc count | 16 |
copper sulfate | 16 |
may involve | 16 |
workplace violence | 16 |
topics lyme | 16 |
transgene expression | 16 |
apical surface | 16 |
radioactive material | 16 |
may exhibit | 16 |
elementary school | 16 |
respondents reported | 16 |
high frequency | 16 |
significant proportion | 16 |
introduced species | 16 |
laboratory data | 16 |
third trimester | 16 |
multiple doses | 16 |
terrorist attack | 16 |
surface proteins | 16 |
one million | 16 |
high index | 16 |
factors influencing | 16 |
least three | 16 |
hiv prevalence | 16 |
cancer imaging | 16 |
complement fixation | 16 |
donor screening | 16 |
high doses | 16 |
zoonotic infections | 16 |
biomedical research | 16 |
case definitions | 16 |
population groups | 16 |
incubation periods | 16 |
scientific knowledge | 16 |
alternative medicine | 16 |
asian countries | 16 |
term follow | 16 |
feel comfortable | 16 |
small round | 16 |
health plans | 16 |
laboratory personnel | 16 |
based studies | 16 |
nursing staff | 16 |
seek medical | 16 |
residual disease | 16 |
weapons program | 16 |
cranial nerve | 16 |
infectious material | 16 |
disease characterized | 16 |
egg production | 16 |
appropriate antibiotic | 16 |
threat agents | 16 |
laboratory confirmation | 16 |
type i | 16 |
rise building | 16 |
global population | 16 |
will decrease | 16 |
reverse transcription | 16 |
common finding | 16 |
adult population | 16 |
might also | 16 |
infection caused | 16 |
alveolar macrophages | 16 |
native species | 16 |
economic benefits | 16 |
salmonella enterica | 16 |
disease epidemiology | 16 |
adult cattle | 16 |
tge people | 16 |
registry data | 16 |
air transport | 16 |
studies will | 16 |
rna virus | 16 |
fact sheet | 16 |
allow us | 16 |
frequently reported | 16 |
skin infections | 16 |
new drugs | 16 |
mad cow | 16 |
free survival | 16 |
april th | 16 |
immune function | 16 |
limited resources | 16 |
agents include | 16 |
tm system | 16 |
response plans | 16 |
chlamydia psittaci | 16 |
people will | 16 |
may improve | 16 |
sampled isolates | 16 |
pulmonary tb | 16 |
vaccination status | 16 |
effective vaccines | 16 |
median number | 16 |
deaths due | 16 |
via hands | 16 |
fish oil | 16 |
evolutionary dynamics | 16 |
bluetongue virus | 16 |
intellectual property | 16 |
carrier state | 16 |
currently circulating | 16 |
endothelial cells | 16 |
vaccine may | 16 |
predicted fev | 16 |
short time | 16 |
life threatening | 16 |
also possible | 16 |
national government | 16 |
potential impact | 16 |
development bank | 16 |
lead poisoning | 16 |
dis doi | 16 |
healthy infants | 16 |
commonly seen | 16 |
chronic hbv | 16 |
active tb | 16 |
bhk cells | 16 |
persistent infection | 16 |
tropical cyclones | 16 |
susceptible population | 16 |
blood smear | 16 |
human use | 16 |
live oral | 16 |
ussing chamber | 16 |
human activity | 16 |
aeruginosa infection | 16 |
development assistance | 16 |
specific ige | 16 |
asymptomatic infection | 16 |
toxin production | 16 |
last year | 16 |
outdoor recreation | 16 |
neurologic signs | 16 |
food products | 16 |
continuing education | 16 |
global fund | 16 |
probable cases | 16 |
pan american | 16 |
new drug | 16 |
tuberculin skin | 16 |
fda approved | 16 |
new technology | 16 |
will depend | 16 |
weeks later | 16 |
pandemic infl | 16 |
three cases | 16 |
larva migrans | 16 |
antibody levels | 16 |
will include | 16 |
membrane expression | 16 |
nutritional risk | 16 |
epidemiologic data | 16 |
within years | 16 |
wildlife species | 16 |
pediatric intensive | 16 |
human life | 16 |
traumatic stressors | 16 |
lavage fluid | 16 |
aborted fetuses | 16 |
commonly reported | 16 |
wildlife trade | 16 |
including humans | 16 |
hela cells | 16 |
several different | 16 |
distancing measures | 16 |
armed forces | 16 |
york state | 16 |
critically important | 16 |
cutaneous anthrax | 16 |
milk replacers | 16 |
resistant tuberculosis | 16 |
infectious mononucleosis | 16 |
months post | 16 |
recommended vaccines | 16 |
whole cell | 16 |
influenza pandemics | 16 |
much smaller | 16 |
sudden onset | 16 |
people worldwide | 16 |
new mexico | 16 |
development goals | 16 |
percent predicted | 16 |
included patients | 16 |
foot rot | 16 |
sexual partners | 16 |
preventive health | 16 |
infection transmitted | 16 |
emerging pathogen | 16 |
social mobility | 16 |
diarrheal illness | 16 |
may predispose | 16 |
genetic analysis | 16 |
outer surface | 16 |
endemic regions | 16 |
reproductive tract | 16 |
long periods | 16 |
species transmission | 16 |
weekly report | 16 |
become increasingly | 16 |
contagious diseases | 16 |
obstructive pulmonary | 16 |
federal bureau | 16 |
new orleans | 16 |
infective endocarditis | 16 |
mask mandates | 16 |
new guinea | 16 |
stool samples | 16 |
epec gastroenteritis | 16 |
asian american | 16 |
face mask | 16 |
labour market | 16 |
become ill | 16 |
home countries | 16 |
borne relapsing | 16 |
gov research | 16 |
clinical testing | 16 |
exotic species | 15 |
rheumatoid arthritis | 15 |
national association | 15 |
vaginal discharge | 15 |
serious public | 15 |
medical community | 15 |
sexually active | 15 |
ml min | 15 |
outpatient setting | 15 |
hygiene cough | 15 |